GO
Loading...

Biotechnology

More

  • For a Monday before the Thanksgiving holiday, this is turning into an extremely busy day on the biotech beat. Two of the stories actually broke on Sunday: Celgene buying Pharmion for nearly $3 billion and Genentech announcing a breakthrough in brain cancer. Then, before the opening bell this morning Onyx Pharmaceuticals and Bayer won the expected Food and Drug Administration approval of their drug Nexavar for liver cancer.

  • Back To Biotech: Risk & Reward Wednesday, 14 Nov 2007 | 11:06 AM ET

    In 1990, Amgen was the risky-but-profitable biotech of choice. Today, its stand-in is Onyx Pharmaceuticals.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Back To Biotech: Slow & Steady Wednesday, 14 Nov 2007 | 11:03 AM ET

    Count on Celgene and, to a lesser extent, Genentech to keep delivering even through an economic downturn.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Get Immunized: What to Own In a Rough Market Thursday, 25 Oct 2007 | 10:54 AM ET

    Cramer’s shopping list of what to buy when the buying gets tough. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Amgen Profit Climbs; Aranesp Sales Decline Wednesday, 24 Oct 2007 | 5:41 PM ET
    Amgen

    Amgen's  third-quarter earnings  rose from a year ago and beat forecasts. The biotechnology firm reported a profit of $1.18 billion, or $1.08 a share, on sales of $3.6 billion.

  • Amgen: Is There A Takeout Scenario? Wednesday, 24 Oct 2007 | 1:15 PM ET

    On a day when the markets are selling off, shares of the world's biggest biotech company--by sales--are holding their own. There are a few things that could be buoying Amgen's stock. The company won a huge patent battle yesterday, it reports earnings after the closing bell today and an analyst has upgraded the stock to "Outperform".

  • Glaxo's Avandia Nose Dive: What It Means Wednesday, 24 Oct 2007 | 11:48 AM ET

    Shares in the world's second biggest drug company, GlaxoSmithKline, are giving back all of yesterday's gains in early trading this morning. That's because sales of its embattled diabetes drug, Avandia and other Avandia-related products took a huge dive in the third quarter. Down 48% in the U.S. from the same time last year.

  • Biogen Idec Earnings A 'Huge Swing and a Miss' Tuesday, 23 Oct 2007 | 12:13 PM ET

    Biotech giant Biogen Idec posted some disappointing third-quarter results, falling short of Wall Street expectations across the board. Does it matter, since the company has announced it's up for sale? Biotech analyst Christopher Raymond of Robert W. Baird thinks it does.

  • Biogen Earnings Fall Short of Analysts' Targets Tuesday, 23 Oct 2007 | 9:51 AM ET

    Biotechnology company Biogen Idec, which put itself up for sale earlier this month, reported third-quarter earnings and revenue Tuesday that fell short of analysts' expectations.

  • Pharma Stock Picks From a Five-Star Fund Manager Monday, 22 Oct 2007 | 1:05 PM ET

    To a five-star fund manager, it's not how big the stars are, but how brightly they're shining.  In the pharmaceutical field, Kris Jenner of T. Rowe Price finds brightness at both ends of the size spectrum.

  • ImClone, Merck Shares Jump on Erbitux Trial Tuesday, 11 Sep 2007 | 12:41 PM ET

    The cancer drug Erbitux unexpectedly extended survival in a trial of patients with advanced lung cancer, sending shares of its maker, ImClone Systems, soaring as much as 24 percent.

  • Neurochem And Alzheimer's: Breaking Code Not Easy Monday, 27 Aug 2007 | 2:35 PM ET

    Shares of Neurochem today are trading at a new low after the Canadian biotech announced its developmental drug for Alzheimer's didn't work well enough. It is the latest evidence that cracking the code of this complex disease is extremely challenging. We recently did a story on the drug called Alzhemed, the potential AD-drug market and other companies working on treatments/cures at a dementia conference in Washington, DC.

  • Amgen Shares Hit 52-Week Low After Layoff Announcement Thursday, 16 Aug 2007 | 12:36 PM ET

    Amgen shares plunged to a 52-week low on Thursday in the wake of the biotechnology firm’s announcement that it will lay off more than 2,000 and as many as 2,600 employees--or 12 percent to 14 percent of its labor force.

  • Game Plan for the Week of June 11 Friday, 8 Jun 2007 | 7:48 PM ET

    Cramer can recommend any number of stocks for next week’s Game Plan, but in the end their success depends solely on the 10-year Treasury note. Here's how to play it.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Amgen said on Monday it has agreed to buy privately held Ilypsa, which is developing a drug for chronic kidney disease, for $420 million in cash.

  • Biotechnology company Novacea and drug developer Schering-Plough said they signed a licensing agreement for prostate cancer treatment candidate Asentar.

  • Amgen Shares Drop On More Anemia-Drug Fallout Tuesday, 15 May 2007 | 12:00 PM ET

    Another setback for Amgen anemia-drug franchise sent shares of the No. 1 biotechnology company spiraling down as much as 6.6% on Tuesday -- to a 2-1/2-year low -- as more analysts cut their ratings on the beaten-down stock.

  • Biotechnology Partner Story Sunday, 1 Dec 2002 | 12:00 AM ET
  • Biotechnology Slide Show Sunday, 1 Dec 2002 | 12:00 AM ET